Dr. Higgins on management of post-Aquablation blood loss

The inclusion of iTind is reflected in a newly added statement on temporary implanted prostatic devices.

Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.

"The findings suggest that we may need to view urinary symptoms differently, possibly with an emphasis on earlier treatment,” says Blayne Welk, MD, FRCSC, MSc.

The data were presented at the recent American Urological Association Annual Meeting.

“Aquablation is safe and effective based on several years of research,” said urologist Zein K. Nakhoda, MD.

In this installment, Kevin Zorn, MD, FRCSC, FACS, highlights his disease-specific practice, BPH Canada, which he designates as a “one-stop shop” for patients with benign prostatic hyperplasia.